Skip to main content
Top
Published in: Drug Safety 10/2019

Open Access 01-10-2019 | Constipation | Study Design

Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350

Authors: Joan Fortuny, Alicia Gilsenan, Miguel Cainzos-Achirica, Oscar F. Cantero, Robert W. V. Flynn, Luis Garcia-Rodriguez, Bianca Kollhorst, Pär Karlsson, Love Linnér, Thomas M. MacDonald, Estel Plana, Ana Ruigómez, Tania Schink, Ryan Ziemiecki, Elizabeth B. Andrews

Published in: Drug Safety | Issue 10/2019

Login to get access

Abstract

Introduction

Given prior safety experience with other 5-HT4 agonists for chronic constipation, an observational, population-based cohort study in five data sources from Germany, Sweden, and the UK was conducted to evaluate the cardiovascular safety of prucalopride.

Objectives

Our objective is to describe the methods and resulting comparability of cohorts in a multi-database, multinational study of prucalopride initiators and polyethylene glycol 3350 (PEG) initiators following a harmonized protocol.

Methods

Prucalopride initiators were matched on age, sex, and index date to PEG initiators (1:5 ratio). Study exposures, cardiovascular risk factors, and other covariates were identified from healthcare utilization codes harmonized across databases. Cardiovascular outcomes were identified using database-specific algorithms based on diagnosis codes. The propensity score (PS) in each database was estimated using logistic regression, with prucalopride versus PEG as the outcome and including clinically relevant variables associated with major adverse cardiovascular events.

Results

In total, 12,030 prucalopride initiators and 59,985 PEG initiators were identified. After matching and trimming, cohorts from the UK and Sweden were well-balanced for cardiovascular risk factors and cancer. However, in Germany, PEG initiators remained older and sicker than prucalopride initiators. The prevalence of these characteristics also differed from those in the UK and Sweden. The pooled analyses included only data from the UK and Sweden.

Conclusions

Matching, trimming, and PS stratification yielded comparable cohorts in four of five data sources. Use of these methods could not achieve balance for key covariates within the German cohort, likely due to reimbursement differences in Germany.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23(5):461–76.CrossRefPubMed Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23(5):461–76.CrossRefPubMed
2.
go back to reference Wald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Helfrich I, Schuijt C, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26(2):227–36.CrossRefPubMed Wald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Helfrich I, Schuijt C, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26(2):227–36.CrossRefPubMed
3.
go back to reference Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414.CrossRefPubMed Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414.CrossRefPubMed
7.
go back to reference Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.CrossRefPubMed Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.CrossRefPubMed
9.
go back to reference Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf. 2012;21(7):770–4.CrossRefPubMed Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf. 2012;21(7):770–4.CrossRefPubMed
10.
go back to reference Cainzos-Achirica M, Ruigómez A, MacDonald TM, García-Rodríguez L, Fortuny J, Flynn RWV, et al. Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 24-28 2019. Cainzos-Achirica M, Ruigómez A, MacDonald TM, García-Rodríguez L, Fortuny J, Flynn RWV, et al. Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 24-28 2019.
11.
go back to reference Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56.CrossRefPubMedPubMedCentral Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56.CrossRefPubMedPubMedCentral
12.
go back to reference Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17(12):1218–25.CrossRefPubMed Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17(12):1218–25.CrossRefPubMed
14.
go back to reference Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;307(6908):846–8.CrossRefPubMedPubMedCentral Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;307(6908):846–8.CrossRefPubMedPubMedCentral
Metadata
Title
Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350
Authors
Joan Fortuny
Alicia Gilsenan
Miguel Cainzos-Achirica
Oscar F. Cantero
Robert W. V. Flynn
Luis Garcia-Rodriguez
Bianca Kollhorst
Pär Karlsson
Love Linnér
Thomas M. MacDonald
Estel Plana
Ana Ruigómez
Tania Schink
Ryan Ziemiecki
Elizabeth B. Andrews
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2019
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-019-00836-z

Other articles of this Issue 10/2019

Drug Safety 10/2019 Go to the issue